Attovia Therapeutics, Inc. (ATTO)

NASDAQ: ATTO · Real-Time Price · USD

15.13

-0.68 (-4.30%)

At close: Nov 13, 2026, 4:00 PM EST

15.22

+0.08 (0.56%)

After-hours: Nov 13, 2026, 4:10 PM EST

Attovia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	1.44	1.35	-
Revenue Growth	-	-	-
Cost of Revenue	72.37	54.15	33.86
Gross Profit	-70.93	-52.8	-33.86
Selling, General & Admin	14.68	14.36	7.69
Operating Expenses	14.68	14.36	7.69
Operating Income	-85.62	-67.16	-41.55
Interest & Investment Income	6.86	6.63	3.44
Other Non Operating Income (Expenses)	-0.12	-0.1	-1.69
Pretax Income	-78.87	-60.63	-39.8
Net Income	-78.87	-60.63	-39.8
Net Income to Common	-78.87	-60.63	-39.8
Net Income Growth	-	-	-
Shares Outstanding (Basic)	11	4	4
Shares Outstanding (Diluted)	11	4	4
Shares Change	-	11.84%	-
EPS (Basic)	-7.49	-15.35	-11.27
EPS (Diluted)	-7.49	-15.35	-11.27
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-78.38	-61.51	-36.81
Free Cash Flow Per Share	-7.44	-15.57	-10.42
Operating Margin	-5945.49%	-4974.74%	-
Profit Margin	-5477.22%	-4490.89%	-
Free Cash Flow Margin	-5442.78%	-4556.44%	-
EBITDA	-84.65	-66.36	-41.24
D&A For EBITDA	0.97	0.8	0.31
EBIT	-85.62	-67.16	-41.55
Revenue as Reported	1.44	1.35	-

SEC Filings: 10-K · 10-Q